(Adnkronos)
“I have seen a change of gear in the management of the monoclonal antibody issue” against Covid-19. This is the vision of Massimo Clementi, director of the Laboratory of Microbiology and Virology at the San Raffaele hospital in Milan, and a professor at the same University. “I believe that the president of Aifa”, the Italian drug agency, “Giorgio Palù, has paid more attention and accelerated. And at least as far as the trials are concerned, I believe a definitive choice has been made to do them. results that have been achieved with Eli Lilly’s formulation would have been singular that a closure still persisted “.
“I see a change of direction”, the expert who has long been among the scientists who have been hoping for commitment to explore the potential of this possible weapon against Covid explains to Adnkronos Salute. “It remains a bit to explain why there was this initial closure. Italy is also at stake. There is an Italian monoclonal and there are other studies underway a little further back. Even the University of Tor Vergata is working on it. And it would be a shame to miss these opportunities that could be offered by science. “
Not just vaccines, then. “In the US, the FDA had given the green light to the experimental use of monoclonal antibodies since early December and I know that day after day, from what my colleagues tell me, it is going well and, as also emerged from the Eli Lilly experimentation, there is a remarkable efficacy of antibodies, both when used early in therapy and used in prophylaxis. Having antibodies also means being in the same condition as a vaccinated. Aifa has not opened up to this use. The cost-benefit ratio is not better than the vaccine, but two days of hospitalization avoided pay off the cost of the antibody.
–
